Alto Neuroscience, Stock Current Valuation
| ANRO Stock | 4.31 0.22 5.38% |
Valuation analysis of Alto Neuroscience, helps investors to measure Alto Neuroscience,'s intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 25th of November 2024, Enterprise Value Over EBITDA is likely to drop to -19. In addition to that, Enterprise Value Multiple is likely to drop to -19. Fundamental drivers impacting Alto Neuroscience,'s valuation include:
Price Book 2.0424 | Enterprise Value 184.1 M |
Undervalued
Today
Please note that Alto Neuroscience,'s price fluctuation is relatively risky at this time. Calculation of the real value of Alto Neuroscience, is based on 3 months time horizon. Increasing Alto Neuroscience,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Alto Neuroscience, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Alto Stock. However, Alto Neuroscience,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.31 | Real 11.1 | Target 31.5 | Hype 4.12 | Naive 7.01 |
The intrinsic value of Alto Neuroscience,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Alto Neuroscience,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Alto Neuroscience, helps investors to forecast how Alto stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Alto Neuroscience, more accurately as focusing exclusively on Alto Neuroscience,'s fundamentals will not take into account other important factors: Alto Neuroscience, Company Current Valuation Analysis
Alto Neuroscience,'s Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Alto Neuroscience, Current Valuation | 184.12 M |
Most of Alto Neuroscience,'s fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alto Neuroscience, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Alto Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Alto Neuroscience, is extremely important. It helps to project a fair market value of Alto Stock properly, considering its historical fundamentals such as Current Valuation. Since Alto Neuroscience,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alto Neuroscience,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alto Neuroscience,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Alto Neuroscience, has a Current Valuation of 184.12 M. This is 98.72% lower than that of the Pharmaceuticals sector and 96.04% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.89% higher than that of the company.
Alto Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alto Neuroscience,'s direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alto Neuroscience, could also be used in its relative valuation, which is a method of valuing Alto Neuroscience, by comparing valuation metrics of similar companies.Alto Neuroscience, is currently under evaluation in current valuation category among its peers.
Alto Neuroscience, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Alto Neuroscience,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Alto Neuroscience,'s managers, analysts, and investors.Environmental | Governance | Social |
Alto Fundamentals
| Current Valuation | 184.12 M | ||||
| Shares Outstanding | 26.96 M | ||||
| Shares Owned By Insiders | 13.11 % | ||||
| Shares Owned By Institutions | 75.03 % | ||||
| Number Of Shares Shorted | 3.06 M | ||||
| Price To Book | 2.04 X | ||||
| EBITDA | (34.56 M) | ||||
| Net Income | (36.3 M) | ||||
| Total Debt | 151.46 M | ||||
| Book Value Per Share | 6.67 X | ||||
| Cash Flow From Operations | (33.45 M) | ||||
| Short Ratio | 11.82 X | ||||
| Earnings Per Share | (1.85) X | ||||
| Target Price | 31.5 | ||||
| Market Capitalization | 367.18 M | ||||
| Total Asset | 86.63 M | ||||
| Retained Earnings | (76.97 M) | ||||
| Working Capital | 79.78 M | ||||
| Net Asset | 86.63 M |
About Alto Neuroscience, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alto Neuroscience,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alto Neuroscience, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alto Neuroscience, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Alto Neuroscience,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alto Neuroscience, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alto Neuroscience, will appreciate offsetting losses from the drop in the long position's value.Moving together with Alto Stock
Moving against Alto Stock
| 0.74 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.71 | GILD | Gilead Sciences | PairCorr |
| 0.61 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.58 | KTTAW | Pasithea Therapeutics | PairCorr |
| 0.36 | KZR | Kezar Life Sciences | PairCorr |
The ability to find closely correlated positions to Alto Neuroscience, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alto Neuroscience, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alto Neuroscience, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alto Neuroscience, to buy it.
The correlation of Alto Neuroscience, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alto Neuroscience, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alto Neuroscience, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alto Neuroscience, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Alto Neuroscience, Piotroski F Score and Alto Neuroscience, Altman Z Score analysis. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience,. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.85) |
The market value of Alto Neuroscience, is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience,'s value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience,'s market value can be influenced by many factors that don't directly affect Alto Neuroscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alto Neuroscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Alto Neuroscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.